PhD, Pharmacology, National University of Ireland, University College, Dublin
Research Associate Professor
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine
Member, Cardiovascular Institute, University of Pennsylvania School of Medicine
Research Expertise
Cyclooxygenase (COX) -2, and one of its products prostaglandin (PG) E2, are established as pro-tumorigenic. COX-2 is induced during inflammation and increased levels are associated with poor prognosis in cancer. COX inhibition with non-steroidal anti-inflammatory drugs (NSAIDs) consistently reduces incidence, recurrence and/or mortality in breast and other cancers. NSAIDs that are selective for COX-2 show clinical efficacy but their use is limited because of an associated increase in thrombembolic events. This hazard emerges because of collateral suppression of vascular prostacyclin (PGI2), an anti-thrombotic mediator, during systemic COX-2 inhibition. Our research program aims to define therapeutic strategies to safety target COX-2 and PGE2 in breast cancer. We have a particular emphasis in understanding the paracrine and autocrine functions COX-2-derived mediators within the tumor microenvironment. We use mouse models of targeted deletion of COX-2 and downstream enzymes in distinct cell types to dissect the complexities of tumor-stromal interplay. We are also interested in understanding the thrombotic complications that accompany malignancy and deciphering the role of platelets in tumorigenesis.
Other Affiliations
American Society for Cancer Research
American Heart Association
American Society for Biochemistry and Molecular Biology
American Heart Association
Publications
Click here to see my publications
Researcher/Clinician:
Emer M. Smyth, PhD
Institute for Translational Medicine and Therapeutics
University of Pennsylvania School of Medicine
Room 10-104, Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Office Phone: (215) 573-2323
Lab: 215-898-0255